Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
Not Applicable
Completed
- Conditions
- Type-1 Diabetes Mellitus
- Registration Number
- NCT00603031
- Lead Sponsor
- Hvidovre University Hospital
- Brief Summary
study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
- Age 18-60 years
- Type-1 diabetes diagnosed between 5-40 years of age
- Normal weight(BMI 18-27),
- Insulin treatment from time of diagnosis.
Exclusion Criteria
- Severe complications to diabetes
- Abnormal liver or kidney function
- Haemoglobin below the lower limit
- Macroalbuminuria
- Systemic disease
- Pregnancy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose 2 hours
- Secondary Outcome Measures
Name Time Method maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine) 2 hours
Trial Locations
- Locations (1)
Dept. of Endocrinology, Hvidovre Hospital
🇩🇰Copenhagen, Denmark
Dept. of Endocrinology, Hvidovre Hospital🇩🇰Copenhagen, Denmark